{{Rsnum
|rsid=17054392
|Gene=PALLD
|Chromosome=4
|position=168609107
|Orientation=plus
|GMAF=0.04086
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=PALLD
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 100.0
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 5.4 | 32.7 | 61.9
| ASW | 1.8 | 29.8 | 68.4
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 1.8 | 23.6 | 74.5
| MEX | 0.0 | 6.9 | 93.1
| MKK | 3.2 | 26.9 | 69.9
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto GWAS
|PMID=18521091
|Trait=Response to iloperidone treatment (QT prolongation)
|Title=Whole genome association study identifies polymorphisms associated with QT prolongation during iloperidone treatment of schizophrenia
|RiskAllele=C
|Pval=0.0000030000000000000001
|OR=NR
|ORtxt=NR
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs17054392
|overall_frequency_n=10
|overall_frequency_d=126
|overall_frequency=0.0793651
|n_genomes=8
|n_genomes_annotated=0
|n_haplomes=9
|n_articles=0
|n_articles_annotated=0
|in_gwas=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}